News

Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? That disconnect matters for companies developing other […]

CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.

CRISPR Therapeutics AG (CRSP) closed at $59.03 in the latest trading session, marking a +1.2% move from the prior day.

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.

The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

CRISPR Therapeutics (CRSP) is drawing fresh attention as investors digest management’s recent comments on faster CASGEVY uptake and prepare for an earnings update that is expected to show higher revenue and a smaller loss. CRISPR Therapeutics has seen momentum cool recently, with the share price down 5.4% over the past week and 3.2% over the last month, while the 1-year total shareholder return has declined 15.3%. This follows a 3-year total shareholder return of 9.3% and a 5-year total...

CRISPR Therapeutics AG (CRSP) reached $51.8 at the closing of the latest trading day, reflecting a -2.19% change compared to its last close.

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CRISPR Therapeutics (NASDAQ:CRSP) CEO Sam Kulkarni outlined the company’s commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected data updates across several pipeline programs by the end of 2026. Kulkarni said the company’s stra

Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The company had fallen out of investor favor; its recovery was impressive.

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.

CRISPR's expanding pipeline could unlock significantly more value by 2031.

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRISPR Therapeutics stock has climbed in the shorter term but still carries a heavy five year loss, and current valuation checks point to a company that does not clearly screen as either cheap or expensive. For investors looking at CRISPR Therapeutics today, the share price near US$56.82 sits against a mixed valuation read and a long term track record that remains in the red. The stock has fallen 52.9% over 5 years, which means long term holders are still under water despite more recent...

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.

This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.

Blue Bird (NASDAQ:BLBD) reported fiscal 2026 third-quarter revenue of $517 million and adjusted EBITDA of $71 million, as the school-bus manufacturer said it exceeded its guidance across metrics and raised its full-year adjusted EBITDA outlook. The company also announced an expanded collaboration w

Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercia

Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.

CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.

CRISPR Therapeutics Stock Reaction To Recent Trading Session CRISPR Therapeutics (NasdaqGM:CRSP) recently finished a trading session with a positive price move that outpaced the S&P 500. The stock is drawing attention as investors look ahead to its upcoming earnings report. See our latest analysis for CRISPR Therapeutics. At a share price of US$47.99, CRISPR Therapeutics has seen short term momentum cool, with a 30 day share price return down 13.72% and a 1 year total shareholder return down...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $48.44, moving +1.68% from the previous trading session.

Analysts remain optimistic that the market will view upcoming catalysts in a bullish light.

These stocks have market caps below $5 billion, but they could be much more valuable in the future.